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type. These diseases involve blood, bone marrow,
lymph nodes, and other organs. Three morphologic sub-
types of small lymphocytic malignancies of B-cell
type have been recognized: (1) chronic lymphocytic
leukemia (CLL), (2) small lymphocytic malignant lym-
phoma, and (3) small lymphocytic-plasmacytoid malig-
nant lymphoma. Presence or absence of blood involve-
ment and plasmacytoid differentiation distinguish these
subtypes.1
Rai and colleagues2 classified CLL in 0 to IV clinical
stages: stage 0, lymphocytosis in blood and marrow
only; stage I, lymphocytosis associated with enlarged
nodes; stage II, lymphocytosis with splenomegaly
or/and hepatomegaly; stage III, lymphocytosis with
anemia (<110 g/L); and stage IV, lymphocytosis with
thrombocytopenia (<100 platelets/mm3). Lymphaden-
opathy may or may not be present in stages II to IV.
A ging of the cardiac surgical population in most adultcardiac surgical centers in recent times has focused
attention on associated comorbidities, possible compli-
cations, and expected outcomes in the elderly popula-
tion. Lymphocytic malignant disease is a comorbidity
in this subset of aged patients.
Most small lymphocytic malignancies are of B-cell
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CARDIAC OPERATIONS IN PATIENTS WITH LOW-GRADE SMALL LYMPHOCYTIC MALIGNANCIES
Splenomegaly and hepatomegaly are not essential fea-
tures in stages III and IV.
For expedient clinical decision making, the Rai stag-
ing system of CLL has been modified into 3 groups by
estimating the disease severity and prognosis: low-,
intermediate-, and high-risk groups. Rai stage 0 is con-
sidered to indicate a low-risk group, in which the
duration of survival is similar to that of the “normal”
population and therapy is not indicated. The inter-
mediate-risk group comprises Rai stages I and II, and
the high-risk group comprises Rai stages III and IV.
These risk groups are similar to three stages A, B, and
C of the Binet system3 and signify similar prognoses.
Similarly the classification of non-Hodgkin lym-
phoma (NHL) has evolved through several changes into
a clinically relevant Working Formulation widely used
in the United States. In the Working Formulation, the
lymphomas are categorized again as low grade, inter-
mediate grade, and high grade, indicating aggressive-
ness of the neoplasm.
The natural history after treatment of Rai stage 0 or
modified Rai low-risk or Binet stage A of CLL and
low-grade NHL in the Working Formulation appears to
have similar estimated survival and similar biologic
behavior. Recently the International Lymphoma Study
Group proposed a more comprehensive and complex
REAL (Revised European-American Lymphoma) clas-
sification covering NHL, lymphoid leukemias, plasma
cell neoplasms, and Hodgkin disease.4 It takes into con-
sideration morphologic and functional properties of the
neoplastic cells and the stage of maturation of the lin-
eage cell (B or T cell). Both CLL and low-grade NHL
appear to originate from the stage of B-cell pre-antigen
exposure.
Leukemia has been anecdotally observed as a comor-
bidity in elderly patients requiring cardiac surgery.5-7
Myocardial ischemia caused by external compression
of the left main coronary artery by mediastinal lym-
phoma has been reported.8 NHL directly involving the
heart has been reported only twice in the surgical liter-
ature.9,10 There are very few focused surgical
reports11-13 of cardiac operations in patients with CLL.
All of them indicated a possible increase in postopera-
tive infection rate. From this perspective, we reviewed
the Royal Perth Hospital experience of cardiac opera-
tions in this subset of patients.
Patients and methods
From January 1977 through June 1998, 13 patients with
documented B-cell small lymphocytic malignancies under-
went cardiac operations.
CLL was diagnosed before the operation in 8 patients. CLL
was diagnosed by the minimum criterion of lymphocytosis in
peripheral blood (>5 · 109/L). The diagnosis was a preoper-
ative surprise on routine hematologic work-up in 2 of them.
The remaining 5 patients, preoperatively having a diagnosis
of small lymphocytic malignant lymphoma, were considered
to have NHL. 
The status of all patients was also categorized into low-risk
(A), intermediate-risk (B), and high-risk (C) clinical stages.
Clinical records of all patients were retrospectively ana-
lyzed. Current follow-up was conducted by telephone with
their general practitioners about their recent cardiac and lym-
phocytopathologic status. All variables were expressed as
mean ± standard error.
Results
The mean age of the 13 patients was 72.0 ± 2.1 years.
They represented 0.1% of all patients undergoing coro-
nary artery bypass grafting (CABG), 0.07% of all
patients having valve procedures, and 0.08% of all
patients having cardiac operations. Ten patients were
more than 65 years old and represented 0.63% of all
patients undergoing cardiac surgery who were older
than 65 years.
Table I details the clinical data. Although the hemato-
logic diagnosis was a preoperative surprise in 2 patients,
the average preoperative duration of lymphocytopatho-
logic disease was 6.1 ± 1.6 years. Twelve of the patients
were in low-risk clinical stage A. All patients with NHL
had low-grade lymphomas (Working Formulation) with
small cleaved cells. Only 1 patient (with NHL) had
received preoperative chemotherapy with chlorambucil.
Preoperative anemia was present in 4 patients with CLL
and 1 patient with NHL.
Isolated CABG was performed in 11 patients, CABG
with mitral valve replacement (MVR) in 1, and MVR
with aortic valve replacement (AVR) in 1 patient. An
average 3.1 ± 1.2 vessels were grafted. The left internal
thoracic artery was used as a conduit in 8 patients.
Table II details the perioperative data. Stay in the
intensive care unit was prolonged in 3 patients with
CLL (72 hours, 96 hours, and 96 hours) and in 1 patient
with NHL (72 hours); 2 of them had undergone emer-
gency CABG. One patient had required intra-aortic
balloon pumping. Perioperative myocardial infarction
with a significant rise of cardiac enzymes was noticed
in only these 2 patients.
All patients received routine prophylaxis in confor-
mity with the antibiotic regimen of the period. During
this decade various antibiotic regimens (floxacillin
[INN: flucloxacillin] with gentamicin/ceftriaxone/van-
comycin) have been used in this unit. Postoperative
superficial sternal wound infection was noticed in 1
patient with NHL and leg wound infections in 2
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patients with CLL, but their postoperative hospital
stays were not prolonged. The causative microbes were
Klebsiella and Pseudomonas. One patient with CLL
undergoing MVR and AVR had a blood culture grow-
ing Pseudomonas aeruginosa and was treated with
intravenous antibiotics for 6 weeks. The same patient
had required postoperative intra-aortic balloon pump-
ing. Average postoperative hospital stay was 10.0 ± 1.7
days. It was extended to 14 days because of postopera-
tive atrial fibrillation in only 1 patient with CLL who
underwent urgent CABG (· 5) for unstable angina.
There was no hospital death. Follow-up was available
for all patients. There was 1 late death 4 years after
MVR and CABG in a patient with CLL. He had under-
gone AVR and coronary stenting 3 years after his first
operation. Angina recurred in 2 other patients: One
patient (CLL) underwent stenting of the right coronary
artery 3 years after CABG · 5. The second patient
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Table I. Clinical data
CLL NHL Total
No. 8 5 13
Sex (male/female) 7/1 4/1 11/2
Age (y)
Mean 76.0 ± 2.1 66.0 ± 2.5 72.0 ± 2.1
Range 64-82 58-71 58-82
Preop clinical stage
A 7 5 12
B 1 0 1
Preop mean duration of CLL/NHL (y) 6.5 5.75 6.1
Preop mean NYHA 2.9 2.6 2.8
Preop Hgb (g/dL) 11.3 ± 1.6 14.8 ± 2.4 14.5 ± 5.3
Preop globulin (g/dL) 30.0 ± 2.8 22.0 ± 4.7 25.5 ± 3.2
Preop TLC (k/mL) 32.1 ± 16.0 7.4 ± 3.5
Preop lymphocytes (k/mL) 26.6 ± 15.6 3.2 ± 0.4
Preop platelets (k/mL) 179.0 ± 42.5 206.4 ± 35.1 192.95 ± 40.3
Preop LV dysfunction 4 1 5
Preop, Preoperative; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; NYHA, New York Heart Association; Hgb, hemoglobin; TLC, total leuko-
cyte count; LV, left ventricle.
Table II. Perioperative data
CLL NHL Total
Operation
Elective 3 4 7
Urgent 4 0 4
Emergency 1 1 2
CPB time (min) 103.9 ± 17.8 70.3 ± 13.3 92.6 ± 13.2
Crossclamp time (min) 59.7 ± 11.4 40.2 ± 10.7 61.0 ± 9.0
Units of blood/products given per 
patient 
Packed RBC (avg) 2.6 1.6 2.2
Fresh frozen plasma (avg) 0.9 1.6 1.1
Platelets (avg) 3.4 0.9 2.6
ICU stay (h) 49.5 ± 12.7 39.0 ± 11.3 43.4 ± 8.6
Postop hospital stay (d) 11.2 ± 2.2 7.6 ± 0.8 10.0 ± 1.7
Follow-up duration (mo)
Range 7-76 8-23 7-76
Mean 36.3 ± 9.4 20.6 ± 5.7 30.3 ± 6.4
Current CLL/NHL stage
A 5 4 9
B 1 1 2
C 1 0 1
CLL, Chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; CPB, cardiopulmonary bypass; RBC, red blood cell; avg, average; ICU, intensive care unit;
Postop, postoperative.
(NHL) had implantation of a cardioverter-defibrillator
1 year after primary CABG for inducible ventricular
tachycardia on electrophysiologic studies. 
Three patients required chemotherapy during the fol-
low-up period. One of them had pancytopenia develop
after cyclophosphamide therapy after progression of
CLL to stage IV and died of profound sepsis and
obstructive jaundice caused by extrahepatic cholestasis.
Another patient with CLL received a course of chlo-
rambucil 3 years after the operation because of pro-
gression of CLL. The third patient (with NHL) required
3 cycles of chemotherapy (cyclophosphamide, doxoru-
bicin [Adriamycin}, vincristine, and prednisolone)
with subsequent remission. Lymphocytopathologic sta-
tus remained stable in the remaining 10 patients (4 with
NHL and 6 with CLL).
Discussion
Lymphocytic malignant diseases are afflictions of
elderly patients, the median age at diagnosis being
above 61 years. Occurrence in patients below 30 years
of age is rare. In CLL 90% of patients are more than 50
years of age and 70% are more than 60 years old.14 Rai
and associates2 estimated that although some patients
with CLL may die within 1 year after diagnosis, a large
number of them will live longer than 10 years.
Monoclonal expansion of B cells is etiogenic of CLL
in 95% of cases. Only 5% of CLLs arise from T cells,
usually with skin involvement. Immune deficiency
states are known to occur with some of these B-cell
lymphopathies. The natural history of CLL has been
changing during the past 3 decades. Currently, the
patients are much older and a large proportion of them
are in the low-risk Binet A clinical stage.15 Estimated
survivals are as follows: stage A, 10 to 12.5 years; stage
B, 7 to 8 years; and stage C, 2.5 to 3.5 years.16,17
Low-grade NHLs are slow-growing indolent neo-
plasms with estimated median survivals of 8 to 10 years
untreated. They are responsive to chemotherapy, but
treatment does not prolong survival. They can transform
into high-grade lymphomas and behave aggressively.
All but 1 of our patients with CLL were in a low-risk
group at the time of operation; 2 of them progressed to
stage B and C during the follow-up. Similarly, all but 2
patients with NHL continued to have low-grade disease
during the follow-up. Mean age at operation was 72.0
± 2.1 years. The natural life expectancy in Western
Australia is 75 years for men and 80.7 years for
women. Thus significant attrition of life expectancy has
not been noted in this subset of patients with low-grade
B-cell malignant disease. Lack of operative mortality
in this reported group compares favorably with that of
the general cardiac surgical population.
Postoperative pneumonia has been noted in 4 (13%)
of 30 previously reported cases of CLL (Table III). It
was not observed in the present series, although post-
operative atelectasis was noticed in 2 patients.
Postoperative chest or leg wound infection was noticed
in 3 patients, an incidence that was not remarkably dif-
ferent from that observed in other patients undergoing
cardiac operations. Neither intensive care unit stay nor
postoperative hospital stay nor perioperative morbidity
was longer in this group of patients than in patients
having general cardiac surgery. Systemic inflammatory
response and immunologic changes after routine car-
diopulmonary bypass have been studied in the past. 
The immune response pattern has also been noted to
be altered in elderly patients. The extent of such sub-
clinical immune changes in these immunocompro-
mised patients after cardiac surgery has not been re-
ported in the literature. Progression of cardiac disease
in 3 patients during follow-up reflected the usual
natural history and is possibly uninfluenced by the
comorbidity. 
CLL has been observed to be a cause of late death.7
Progress of CLL from intermediate-risk to high-risk
stage possibly contributed to the only late death in this
series in a 79-year-old patient.
Progression of NHL in 1 patient could be reversed
with chemotherapy during follow-up. No specific pre-
operative variable could be identified in these patients
to prognosticate perioperative infection or progression
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Table III. Literature review of cardiac surgery in CLL
First author Place Year No Age (y) Sex
Galvin6 United Kingdom 1988 1 >70
Paccagnella12 Italy 1988 1 62 M
Fox11 United States 1988 2 62, 69 M
Finck13 United States 1993 26 60-79 (69.6 ± 4.9) 19 M, 7 F 
Ghosh Australia 1999 8 64-82 7 M, 1 F
Preop, Preoperative; AVR, aortic valve replacement; chemo, chemotherapy; POD, postoperative day; M, male; F, female; CABG, coronary artery bypass grafting; 
MVR, mitral valve replacement.
of lymphocytopathologic disease or cardiac status.
However, Finck and associates13 had observed “signif-
icant difference in absolute neutrophil count” between
their 6 patients in whom postoperative infection devel-
oped (4.3 ± 2.1 · 109/L) and 20 patients in whom infec-
tion did not develop (6.1 ± 3.4 · 109/L). 
In conclusion, the expected outcome after cardiac
surgery in patients with low-grade B-cell malignant
disease parallels the result in the similar elderly age
groups. However, the possible risk of postoperative
infection, progression of cardiac disease, and lympho-
proliferative state should call for caution.
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Operation Preop treatment Outcome
AVR
AVR Preop chemo, steroid Postop pneumonia, POD 5
CABG Preop chemo in 1 Uneventful
CABG (+assoc operation in 7) Pneumonia in 3; death in 2
CABG in 6; CABG + MVR in 1; AVR + MVR in 1 Leg wound infection in 2
